Genentech in-licenses prostate cancer program

Genentech has agreed to license an experimental therapy for prostate cancer from Protein Design Labs. No details were released, but Protein Design will receive an upfront fee and milestones for the successful development of a therapy. Protein Design had originally in-licensed the program from Seattle Genetics.

- read this story from the AP for more

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.